NAMS NewAmsterdam Pharma
- 18.030
- +0.210+1.18%
- 18.030
- 0.0000.00%
NewAmsterdam Pharma News
Piper Sandler Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $37
Analysts Conflicted on These Healthcare Names: Allakos (ALLK), Edwards Lifesciences (EW) and NewAmsterdam Pharma Company (NAMS)
NewAmsterdam Pharma Price Target Maintained With a $37.00/Share by Piper Sandler
NewAmsterdam Pharma Analyst Ratings
Piper Sandler Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $37
Piper Sandler Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)
RBC Capital Reiterates Outperform on NewAmsterdam Pharma, Maintains $31 Price Target
RBC Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $31
Needham Initiates NewAmsterdam Pharma(NAMS.US) With Buy Rating, Announces Target Price $36
NewAmsterdam Pharma Analyst Ratings
TD Cowen Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating
TD Cowen Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)
NewAmsterdam Pharma Company (NAMS) Gets a Buy From Scotiabank
Strong Buy Rating for NewAmsterdam Pharma Backed by Obicetrapib's Efficacy and Market Potential
Analysts' Top Healthcare Picks: NewAmsterdam Pharma Company (NAMS), Celldex (CLDX)
NewAmsterdam Pharma Analyst Ratings
RBC Capital Reiterates Outperform on NewAmsterdam Pharma, Maintains $31 Price Target
Scotiabank Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $35
Jefferies Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $45
RBC Capital Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)
Analysis
Price Target
No Data
No Data